RAC 1.74% $1.47 race oncology ltd

Intellectual Property (IP) Waterproofing., page-24

  1. 1,258 Posts.
    lightbulb Created with Sketch. 12379
    The benefit of a clinical history and a compound developed when broadness of activity was the goal. Most drugs developed today are highly specialized to a gene or protein. Bisantrene is one of the most sensitive agents I have seen because of how broadly targeting it is. Wonder what happens when you use it properly.

    Here are the tumor agnostic approved drugs.

    Tumor Agnostic Therapies Drug Name
    Larotrectinib (Vitrakvi)
    Entrectinib (Rozlytrek)
    Repotrectinib (Augtyro)
    Pembrolizumab (Keytruda)
    Dostarlimab (Jemperli)
    Dabrafenib and Trametinib (Tafinlar & Mekinist)
    Selpercatinib (Retevmo)
    Fam-trastuzumab deruxtecan (Enhertu)
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.47
Change
0.025(1.74%)
Mkt cap ! $249.7M
Open High Low Value Volume
$1.44 $1.48 $1.44 $25.63K 17.46K

Buyers (Bids)

No. Vol. Price($)
1 312 $1.47
 

Sellers (Offers)

Price($) Vol. No.
$1.48 354 1
View Market Depth
Last trade - 16.10pm 01/11/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.